These differences among participants receiving
various doses were accounted lor, once again, in effectiveness U0126 datasheet analyses that were stratified by propensity score quintile. Using the stratification process, the association in the ordinal logistic regression analysis between each of the variables in the propensity score and antidepressant dose was substantially attenuated. For example, the association of study site with categorical dose was reduced as follows (where Boston was the standard (ie, OR=1.0): New York (OR=2.89; 95% CI: 1.45-5.74; Inhibitors,research,lifescience,medical P=0.002 in unadjusted model vs OR=1.20; 95% CI: 0.72-1.98; P=0.490 in propensity adjusted model); St Louis (OR=1.30; 95% CI: 0.79-2.13; P=0.302 vs OR=.93;95% CI: 0.62-1.40; P=0.717); Iowa (OR=2.61; 95% CI: 1.61-4.24; P<0.001 vs OR=1.35;95% CI: 0.911.99; P=0.138); Chicago (OR=2.49; 95% CI: 1.41-4.41; P=0.002 vs OR=1.16; 95% CI: 0.76-1.77; P=0.484). Similarly, the association of age with categorical dose was reduced as follows (where ages 30 to 39 years was the standard): <30 years (OR=0.51; 95% CI: 0.37-0.71; P<0.001 in unadjusted model Inhibitors,research,lifescience,medical vs OR=0.99; 95% CI: 0.73-1.34; P=0.949 in propensity adjusted model); ages 40 to 49 (OR=1.11; Inhibitors,research,lifescience,medical 95% CI: 0.86-1.42; P=0.435 vs OR=1.01; 95% CI: 0.80-1.29; P=0.913); ages 50 to 59 (OR=1.31; 95% CI: 0.90-1.90; P=0.156 vs OR=1.13; 95% CI: 0.83-1.54; P=0.450); ages 60+ (OR=1.34; 95% CI: 0.87-2.07;
P=0.188 vs OR=1.01; 95% CI: 0.74-1.36; P=0.971). Treatment effectiveness analyses The effectiveness analyses were conducted Inhibitors,research,lifescience,medical with a mixed-effects grouped-time survival model to examine the time until recurrence, which was defined as the number of consecutive weeks during which the categorical antidepressant dose remained unchanged during a “well” period (as defined by RDC19).The
quintile-specilic treatment effectiveness results were pooled because, once again, the treatment by propensity interaction was not statistically significant (-2LL=6:146; df=12; P=0.909). The pooled results indicate that participants treated with higher antidepressant doses were about half as likely to experience a recurrence than those who received no somatic treatment Inhibitors,research,lifescience,medical (odds ratio (OR): 0.50; 95% CI: 0.300.84; Z=-2:60; P=0.009). In contrast, moderate doses were associated with marginal protection (OR: 0.65; 95% CI: 0.41-1.01; Z=-l:92; P=0.055) and lower doses were not associated with significant protection from recurrence (OR: Ribonucleotide reductase 0.98; 95% CI: 0.65-1.48; Z=-0.09; P=0.929). This observational evaluation of maintenance antidepressant treatment provides empirical evidence of the effectiveness of higher categorical doses. As in the acute treatment analyses, the more severely ill subjects were more likely to commence higher doses. Nevertheless, the propensity adjustment allowed for evaluation of maintenance antidepressant interventions in a nonrandomized study with a more broadly generalizable study sample than typically seen in RCTs of antidepressants.